Literature DB >> 24714983

Comprehensive functional annotation of 18 missense mutations found in suspected hemochromatosis type 4 patients.

Isabelle Callebaut1, Rozenn Joubrel2, Serge Pissard3, Caroline Kannengiesser4, Victoria Gérolami5, Cécile Ged6, Estelle Cadet7, François Cartault8, Chandran Ka2, Isabelle Gourlaouen2, Lénaick Gourhant9, Claire Oudin4, Michel Goossens3, Bernard Grandchamp4, Hubert De Verneuil6, Jacques Rochette7, Claude Férec2, Gérald Le Gac10.   

Abstract

Hemochromatosis type 4 is a rare form of primary iron overload transmitted as an autosomal dominant trait caused by mutations in the gene encoding the iron transport protein ferroportin 1 (SLC40A1). SLC40A1 mutations fall into two functional categories (loss- versus gain-of-function) underlying two distinct clinical entities (hemochromatosis type 4A versus type 4B). However, the vast majority of SLC40A1 mutations are rare missense variations, with only a few showing strong evidence of causality. The present study reports the results of an integrated approach collecting genetic and phenotypic data from 44 suspected hemochromatosis type 4 patients, with comprehensive structural and functional annotations. Causality was demonstrated for 10 missense variants, showing a clear dichotomy between the two hemochromatosis type 4 subtypes. Two subgroups of loss-of-function mutations were distinguished: one impairing cell-surface expression and one altering only iron egress. Additionally, a new gain-of-function mutation was identified, and the degradation of ferroportin on hepcidin binding was shown to probably depend on the integrity of a large extracellular loop outside of the hepcidin-binding domain. Eight further missense variations, on the other hand, were shown to have no discernible effects at either protein or RNA level; these were found in apparently isolated patients and were associated with a less severe phenotype. The present findings illustrate the importance of combining in silico and biochemical approaches to fully distinguish pathogenic SLC40A1 mutations from benign variants. This has profound implications for patient management.
© The Author 2014. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24714983     DOI: 10.1093/hmg/ddu160

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  23 in total

1.  Ferroportin deficiency in erythroid cells causes serum iron deficiency and promotes hemolysis due to oxidative stress.

Authors:  De-Liang Zhang; Manik C Ghosh; Hayden Ollivierre; Yan Li; Tracey A Rouault
Journal:  Blood       Date:  2018-09-13       Impact factor: 22.113

2.  Loss-of-function ferroportin disease: novel mechanistic insights and unanswered questions.

Authors:  L Tom Vlasveld; Dorine W Swinkels
Journal:  Haematologica       Date:  2018-11       Impact factor: 9.941

3.  Structure-function analysis of ferroportin defines the binding site and an alternative mechanism of action of hepcidin.

Authors:  Sharraya Aschemeyer; Bo Qiao; Deborah Stefanova; Erika V Valore; Albert C Sek; T Alex Ruwe; Kyle R Vieth; Grace Jung; Carla Casu; Stefano Rivella; Mika Jormakka; Bryan Mackenzie; Tomas Ganz; Elizabeta Nemeth
Journal:  Blood       Date:  2017-12-13       Impact factor: 22.113

4.  Novel diagnostic tool for prediction of variant spliceogenicity derived from a set of 395 combined in silico/in vitro studies: an international collaborative effort.

Authors:  Raphaël Leman; Pascaline Gaildrat; Gérald Le Gac; Chandran Ka; Yann Fichou; Marie-Pierre Audrezet; Virginie Caux-Moncoutier; Sandrine M Caputo; Nadia Boutry-Kryza; Mélanie Léone; Sylvie Mazoyer; Françoise Bonnet-Dorion; Nicolas Sevenet; Marine Guillaud-Bataille; Etienne Rouleau; Brigitte Bressac-de Paillerets; Barbara Wappenschmidt; Maria Rossing; Danielle Muller; Violaine Bourdon; Françoise Revillon; Michael T Parsons; Antoine Rousselin; Grégoire Davy; Gaia Castelain; Laurent Castéra; Joanna Sokolowska; Florence Coulet; Capucine Delnatte; Claude Férec; Amanda B Spurdle; Alexandra Martins; Sophie Krieger; Claude Houdayer
Journal:  Nucleic Acids Res       Date:  2018-09-06       Impact factor: 16.971

Review 5.  Mechanistic and regulatory aspects of intestinal iron absorption.

Authors:  Sukru Gulec; Gregory J Anderson; James F Collins
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2014-07-03       Impact factor: 4.052

6.  Human ferroportin mediates proton-coupled active transport of iron.

Authors:  Shuang Li; Yihu Yang; Weikai Li
Journal:  Blood Adv       Date:  2020-10-13

Review 7.  Ironing out Ferroportin.

Authors:  Hal Drakesmith; Elizabeta Nemeth; Tomas Ganz
Journal:  Cell Metab       Date:  2015-10-01       Impact factor: 27.287

Review 8.  Ethnic Differences in Iron Status.

Authors:  Wanhui Kang; Alexa Barad; Andrew G Clark; Yiqin Wang; Xu Lin; Zhenglong Gu; Kimberly O O'Brien
Journal:  Adv Nutr       Date:  2021-10-01       Impact factor: 8.701

9.  The global prevalence of HFE and non-HFE hemochromatosis estimated from analysis of next-generation sequencing data.

Authors:  Daniel F Wallace; V Nathan Subramaniam
Journal:  Genet Med       Date:  2015-12-03       Impact factor: 8.822

10.  Functional characterization of a novel SLC40A1 Arg88Ile mutation in a kindred with familial iron overload treated by phlebotomy.

Authors:  Jihad Womack; Abitha Sukumaran; Xiuqi Li; Larisa Lozovatsky; Patrick G Gallagher; Jerome E Seid; Karin E Finberg
Journal:  Blood Cells Mol Dis       Date:  2020-12-24       Impact factor: 3.039

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.